The Semax peptide is a synthetic heptapeptide analog of ACTH(4-10) that has become one of the most studied neuroprotective compounds in cognitive research.
Semax is a synthetic heptapeptide analog of ACTH(4-10) — the fragment of adrenocorticotropic hormone responsible for cognitive and neuroprotective effects, separated from the hormonal (cortisol-stimulating) activity of full-length ACTH. Developed at the Institute of Molecular Genetics in Moscow, Semax is approved in Russia as a prescription medication for stroke recovery, cognitive disorders, and optic nerve disease.
What distinguishes Semax peptide from other nootropic compounds is its robust and well-documented upregulation of BDNF (brain-derived neurotrophic factor) — the protein most directly responsible for neuronal growth, synaptic plasticity, and long-term memory formation.
How the Semax Peptide Enhances BDNF
BDNF is often called “fertilizer for the brain.” It promotes the survival of existing neurons, encourages the growth of new neurons and synapses, and strengthens the connections involved in learning and memory. BDNF levels naturally decline with age, stress, and sedentary lifestyle — correlating with cognitive decline, depression, and neurodegenerative disease.
Published research demonstrates that Semax significantly increases BDNF mRNA expression in the hippocampus, prefrontal cortex, and basal forebrain — the brain regions most critical for memory, executive function, and attention. This effect occurs rapidly (within hours of administration) and persists beyond the peptide’s plasma half-life, suggesting downstream gene expression changes.
The Semax peptide also upregulates NGF (nerve growth factor) and GDNF (glial cell-derived neurotrophic factor), broadening its neurotrophic profile beyond BDNF alone.
Neuroprotection Research
Semax was originally developed for and clinically tested in stroke recovery. Published clinical data from Russian medical institutions shows that Semax peptide administration following ischemic stroke improved neurological outcomes and reduced infarct volume. The neuroprotective mechanism involves reducing oxidative stress in ischemic tissue, modulating inflammatory cytokine expression in the CNS, supporting neuronal survival through neurotrophic factor elevation, and promoting angiogenesis in damaged brain tissue.
This neuroprotective profile overlaps with BPC-157‘s neuroprotective properties, though the mechanisms differ. BPC-157 works primarily through nitric oxide modulation and angiogenesis, while Semax works through neurotrophic factor upregulation.
Cognitive Enhancement Research
Beyond neuroprotection, the Semax peptide is studied for cognitive enhancement in healthy models — making it one of the most researched examples of Semax nootropic effects in the scientific literature. Research findings include improved attention and working memory in rodent behavioral tests, enhanced learning acquisition speed, better performance under stress conditions, and modulation of dopaminergic and serotonergic neurotransmission.
Users in the Russian clinical context report improved verbal fluency, faster information processing, and better sustained attention — effects consistent with the BDNF and catecholamine modulation documented in preclinical research.
Semax vs. Other Cognitive Peptides
| Feature | Semax | Selank | Dihexa |
|---|---|---|---|
| Primary Mechanism | BDNF/NGF upregulation | GABA modulation + enkephalin | HGF/c-Met synaptogenesis |
| Primary Effect | Cognitive enhancement | Anxiolytic + cognitive | Synapse formation |
| Anxiety Effects | Mild (indirect via serotonin) | Strong anxiolytic | None documented |
| Sedation | None | None | None |
| Clinical Status | Approved in Russia | Approved in Russia | Preclinical only |
| Administration | Intranasal preferred | Intranasal preferred | Subcutaneous |
| Research Volume | Extensive (Russian + international) | Extensive (primarily Russian) | Limited (single lab origin) |
The Semax + Selank Cognitive Stack
The most common nootropic peptide combination in research is Semax + Selank. The rationale is mechanistic complementarity: Semax provides cognitive enhancement through BDNF upregulation (building new neural connections), while Selank provides anxiolytic support through GABA modulation (removing anxiety interference with cognition). Together, they produce a state researchers describe as “focused calm” — enhanced cognitive performance without the anxiety that typically accompanies stimulant-based nootropics.
For general stacking principles, see the peptide stacking guide.
Administration
Semax is most commonly administered intranasally in published research. The intranasal route provides direct CNS access via the olfactory epithelium, bypassing first-pass metabolism and the blood-brain barrier. Subcutaneous administration is also used but may be less efficient for CNS-targeted effects.
Standard storage and purity verification protocols apply.
FDA Reclassification Status
Semax is expected to return to Category 1 status under the 2026 FDA reclassification, allowing US compounding pharmacies to prepare it. This follows its decades of clinical use in Russia for stroke recovery and cognitive disorders.
Further Reading
For additional peer-reviewed research, see: PubMed research on Semax and BDNF upregulation.
Understanding the Semax peptide and its mechanisms of Semax BDNF upregulation is essential for researchers navigating this rapidly evolving field in 2026. For a direct comparison of these two nootropic peptides, see our Semax vs. Selank comparison guide.
Frequently Asked Questions
Is Semax a stimulant?
No. Semax enhances cognition through neurotrophic factor upregulation, not stimulant mechanisms. It does not produce the jitteriness, crash, or dependency associated with caffeine, amphetamines, or modafinil.
How quickly does Semax work?
Published research shows BDNF upregulation within hours of administration. Subjective cognitive effects are typically reported within days of consistent use, with optimal effects developing over 1-2 weeks.
Can Semax be combined with BPC-157?
Semax (BDNF/cognitive) and BPC-157 (tissue repair/angiogenesis) work through entirely different pathways with no known interactions. Some researchers study both when addressing both cognitive and physical recovery endpoints.
Is Semax the same as ACTH?
No. Semax is derived from the ACTH(4-10) fragment — the portion responsible for cognitive effects. It does not contain the ACTH sequences that stimulate cortisol production. Semax does not affect adrenal function or cortisol levels.
All PSPeptides products are sold exclusively for research and laboratory use.